14. ACQUISITION (Details)		3 Months Ended			12 Months Ended
	Nov. 23, 2015 USD ($) patent	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)
Acquisition disclosure
Discount rate	0.148				0.155
Other accrued expenses
Acquisition disclosure
Contingent consideration liability					$ 2,700,000	$ 4,200,000
MikaMonu
Acquisition disclosure
Cash paid for acquisition	$ 4,900,000
Payment of escrow deposit		$ 1,000,000.0	$ 750,000	$ 743,000
Potential cash retention payments	2,500,000
Change in contingent consideration liability					(1,600,000)	229,000	$ 80,000
MikaMonu | Other accrued expenses
Acquisition disclosure
Contingent consideration liability	$ 5,800,000				2,700,000	$ 4,200,000
MikaMonu | UNITED STATES
Acquisition disclosure
Number of patents held | patent	12
MikaMonu | Continued employment of Dr. Avidan Akerib
Acquisition disclosure
Amount of payment held in escrow	$ 2,500,000
Contingent consideration	1,200,000
MikaMonu | Product development milestones and revenue targets
Acquisition disclosure
Contingent consideration					1,300,000
MikaMonu | Product development milestones and revenue targets | Maximum
Acquisition disclosure
Contingent consideration					$ 32,000,000.0
MikaMonu | Product development milestones and revenue targets | Accrued expenses and other liabilities
Acquisition disclosure
Contingent consideration								$ 750,000
MikaMonu | Quarterly payments based on net revenue | Maximum
Acquisition disclosure
Contingent consideration	$ 30,000,000.0
Contingent consideration, percent of net revenue	5.00%